The Annual European Society for Medical Oncology (ESMO) Congress was held in Munich, Germany from October 19-23, 2018. As to be expected, immunotherapies headlined this year’s conference. In particular, new data was presented for regimens featuring PD-1/PD-L1 inhibitors in melanoma, head and neck cancer, renal cell carcinoma, non-small cell lung cancer, bladder cancer, and breast cancer. Other highlights included trial data from established targeted therapy brands, such as Cyramza, Alecensa, Cabometyx, Lynparza, and Ibrance. Finally, updates on pipeline products with novel mechanisms of action were also presented at the conference, including TLR9 agonist SD- 101, STING agonist MK-1454, farnesyl transferase inhibitor tipifarnib, CXCR4 antagonist POL6326, and TRK inhibitors larotrectinib and entrectinib.

This post-meeting report features summaries of a few key topics along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.